UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549
 
FORM 8-K
 
CURRENT REPORT
 
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):
April 9, 2010
 
TRANSGENOMIC, INC.
(Exact name of registrant as specified in its charter)
 
Delaware
  
000-30975
  
911789357
(State of Incorporation)
  
(Commission File Number)
  
(IRS Employer Identification
       
Number)
         

12325 Emmet Street, Omaha, Nebraska
        68164       
(Address of principal executive offices)
(Zip Code)

 
(402) 452-5400
(Registrant’s telephone number, including area code)
 
Not applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 
Item 5.02           Departure of Officer.
 
Effective as of April 9, 2010, Dr. Eric Kaldjian ceased to be the Chief Scientific Officer of the registrant.
 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
Dated:  April 14, 2010
TRANSGENOMIC, INC.
 
 
 
By:
/s/ Debra A. Schneider
   
Debra A. Schneider
   
Chief Financial Officer